NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...
The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating ...
Jefferies, Goldman Sachs & Co., Leerink Partners, TD Cowen, Guggenheim Securities and William Blair are acting as joint book-running managers for the proposed Offering.
Company announced the commencement of an underwritten public offering of $300M of the company’s ordinary shares, ...
NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated ...
NewAmsterdam is singing data from its Broadway heart disease trial, hailing another phase 3 win for its cholesterol-busting ...
The topline results from the Phase III trial found the treatment to be well tolerated with a reduction in low-density ...
During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma NAMS, revealing diverse outlooks ...
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has earned an average recommendation of “Buy” from the six research firms ...
Check the time stamp on this data. Updated AI-Generated Signals for Newamsterdam Pharma Company N.v. Warrant (NAMSW) ...
NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock ...